复星医药子公司复宏汉霖H药启航印度

Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has successfully delivered the first batch of its self-developed anti-PD-1 monoclonal antibody, H drug, to the Indian market, marking its entry into the world's most populous country and addressing urgent clinical needs in small cell lung cancer (SCLC) [1] Company Summary - Fuhong Hanlin's H drug, also known as Hanshuang and Sru Li monoclonal antibody, is the first anti-PD-1 monoclonal antibody approved for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) globally [1] - The drug has received approval for marketing in nearly 40 countries and regions, including China, the UK, Germany, India, Indonesia, and Singapore, covering nearly half of the global population [1]